Axonics, Inc. (NASDAQ:AXNX) Shares Acquired by Jennison Associates LLC

Jennison Associates LLC increased its stake in Axonics, Inc. (NASDAQ:AXNX - Free Report) by 56.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 354,331 shares of the company's stock after purchasing an additional 128,374 shares during the quarter. Jennison Associates LLC owned 0.70% of Axonics worth $22,050,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. SG Americas Securities LLC grew its holdings in shares of Axonics by 763.5% in the third quarter. SG Americas Securities LLC now owns 18,134 shares of the company's stock worth $1,018,000 after acquiring an additional 16,034 shares during the period. Exchange Traded Concepts LLC bought a new stake in Axonics during the third quarter valued at about $37,000. North Growth Management Ltd. bought a new stake in Axonics during the third quarter valued at about $1,437,000. Commonwealth Equity Services LLC bought a new stake in Axonics during the third quarter valued at about $230,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Axonics by 13.6% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,588 shares of the company's stock valued at $594,000 after purchasing an additional 1,269 shares during the period. Hedge funds and other institutional investors own 99.48% of the company's stock.

Axonics Trading Up 0.2 %

Shares of NASDAQ:AXNX traded up $0.15 during mid-day trading on Friday, reaching $66.69. The stock had a trading volume of 318,433 shares, compared to its average volume of 1,249,882. The company has a market cap of $3.40 billion, a P/E ratio of -512.04 and a beta of 0.56. Axonics, Inc. has a 1 year low of $47.59 and a 1 year high of $69.68. The business's 50 day moving average price is $67.92 and its 200 day moving average price is $62.71.

Axonics (NASDAQ:AXNX - Get Free Report) last issued its quarterly earnings data on Wednesday, February 28th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.07. Axonics had a negative return on equity of 1.00% and a negative net margin of 1.66%. The business had revenue of $109.70 million for the quarter, compared to the consensus estimate of $107.33 million. During the same period in the prior year, the business posted $0.01 earnings per share. The company's quarterly revenue was up 27.7% compared to the same quarter last year. Analysts predict that Axonics, Inc. will post 0.32 earnings per share for the current fiscal year.

Insider Buying and Selling at Axonics

In other Axonics news, CFO Kari Leigh Keese sold 3,489 shares of the company's stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $67.74, for a total transaction of $236,344.86. Following the sale, the chief financial officer now directly owns 43,323 shares in the company, valued at $2,934,700.02. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, EVP John Woock sold 15,899 shares of the stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $67.74, for a total value of $1,076,998.26. Following the sale, the executive vice president now directly owns 77,403 shares in the company, valued at $5,243,279.22. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Kari Leigh Keese sold 3,489 shares of the stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $67.74, for a total value of $236,344.86. Following the completion of the sale, the chief financial officer now owns 43,323 shares in the company, valued at $2,934,700.02. The disclosure for this sale can be found here. Insiders have sold a total of 65,837 shares of company stock worth $4,459,798 over the last ninety days. Company insiders own 1.85% of the company's stock.

Wall Street Analyst Weigh In

AXNX has been the subject of several recent research reports. Piper Sandler reissued a "neutral" rating and set a $71.00 price target (down previously from $75.00) on shares of Axonics in a report on Friday, January 12th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $71.00 price objective on shares of Axonics in a research note on Thursday, February 29th. SVB Leerink reaffirmed a "market perform" rating and issued a $71.00 price objective on shares of Axonics in a research note on Friday, January 12th. Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $71.00 price objective (up previously from $68.00) on shares of Axonics in a research note on Wednesday, January 10th. Finally, Wolfe Research lowered Axonics from an "outperform" rating to a "peer perform" rating in a research note on Tuesday, January 9th. Eight analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, Axonics presently has an average rating of "Hold" and a consensus target price of $70.73.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.